Chordia Therapeutics (190A.T) traded down -3.85 % during a 24 hours period ending at 05:13 PM Central Europe on Monday 26th. One Chordia Therapeutics stock can currently be bought for about JPY 50 on popular exchanges. Current supply of Chordia Therapeutics stocks is 77.2 mn. Chordia Therapeutics has a current market capitalization of JPY 3.9 bn and approximately JPY 41.3 mn worth of Chordia Therapeutics was traded on exchanges in the last 24 hours. Since last month end, Chordia Therapeutics has traded -28.57 % down. Simple moving average of last 200 days is at JPY 100.81. The highest price of past 52 weeks was recorded at JPY 179 on 03/02/2026. 52 weeks low was at JPY 47 on 10/23/2026.

Here is how related stocks have performed in the past 24 hours:

  • Plat’home (6836.T) traded down -0.82 % and now trades at JPY 952. Current market capitalisation for Plat’home is JPY 4.6 bn. Current price/earnings ratio for Plat’home is 208.39.

  • Every (607A.T) traded flat 0 % and now trades at JPY 221. Current market capitalisation for Every is JPY 4.6 bn.

  • Vector (2656.T) traded down -1.41 % and now trades at JPY 143. Current market capitalisation for Vector is JPY 4.6 bn.

  • Ymirlink (4372.T) traded flat 0 % and now trades at JPY 1,140. Current market capitalisation for Ymirlink is JPY 4.6 bn. Ymirlink has a current price to earnings ratio of 12.94.

  • Nihon Enterprise (4829.T) traded down -13.04 % and now trades at JPY 118. Nihon Enterprise has a market capitalisation of JPY 4.6 bn. Current price/earnings ratio for Nihon Enterprise is 93.26.

About Chordia Therapeutics

Chordia Therapeutics Inc. is a biotechnology company based in Japan that operates on the Tokyo Stock Exchange. The company is focused on developing therapies for various neurological disorders, particularly those involving the central nervous system. Their current research involves exploring the potential of cell-based therapies for treating such conditions as amyotrophic lateral sclerosis and Parkinson’s disease. Additionally, they are also working towards finding novel targeted therapies through their proprietary drug discovery platform.